LivaNova (NASDAQ:LIVN) Hits New 52-Week Low – What’s Next?

LivaNova PLC (NASDAQ:LIVN) shares hit a new 52-week low during trading on Thursday . The stock traded as low as $40.03 and last traded at $40.02, with a volume of 70886 shares trading hands. The stock had previously closed at $40.87.

Analyst Ratings Changes

Several brokerages have recently commented on LIVN. Mizuho reduced their target price on LivaNova from $70.00 to $60.00 and set an “outperform” rating for the company in a research note on Wednesday, February 26th. Wolfe Research downgraded LivaNova from an “outperform” rating to a “peer perform” rating in a research note on Wednesday, February 26th. Barclays dropped their price target on shares of LivaNova from $58.00 to $56.00 and set an “equal weight” rating on the stock in a research report on Friday. StockNews.com cut shares of LivaNova from a “strong-buy” rating to a “buy” rating in a research report on Wednesday, February 26th. Finally, Needham & Company LLC dropped their price target on shares of LivaNova from $75.00 to $64.00 and set a “buy” rating on the stock in a research report on Wednesday, February 26th. Two research analysts have rated the stock with a hold rating, six have assigned a buy rating and one has given a strong buy rating to the stock. According to MarketBeat.com, LivaNova currently has a consensus rating of “Moderate Buy” and an average target price of $61.17.

LivaNova Stock Performance

The company’s 50-day simple moving average is $46.79 and its 200 day simple moving average is $49.32. The company has a current ratio of 3.37, a quick ratio of 2.87 and a debt-to-equity ratio of 0.46. The stock has a market cap of $2.13 billion, a P/E ratio of 93.26 and a beta of 1.10.

Insiders Place Their Bets

In related news, Director Francesco Bianchi sold 1,250 shares of LivaNova stock in a transaction that occurred on Wednesday, December 11th. The shares were sold at an average price of $50.99, for a total value of $63,737.50. Following the sale, the director now owns 7,522 shares of the company’s stock, valued at approximately $383,546.78. The trade was a 14.25 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Insiders own 0.27% of the company’s stock.

Institutional Inflows and Outflows

A number of hedge funds have recently bought and sold shares of the business. Russell Investments Group Ltd. grew its position in shares of LivaNova by 17.1% during the 4th quarter. Russell Investments Group Ltd. now owns 1,502 shares of the company’s stock valued at $70,000 after purchasing an additional 219 shares in the last quarter. Summit Investment Advisors Inc. grew its position in shares of LivaNova by 1.7% during the 4th quarter. Summit Investment Advisors Inc. now owns 16,846 shares of the company’s stock valued at $780,000 after purchasing an additional 289 shares in the last quarter. Atria Investments Inc grew its position in shares of LivaNova by 6.2% during the 3rd quarter. Atria Investments Inc now owns 5,653 shares of the company’s stock valued at $297,000 after purchasing an additional 331 shares in the last quarter. State of Alaska Department of Revenue grew its position in shares of LivaNova by 7.3% during the 3rd quarter. State of Alaska Department of Revenue now owns 6,246 shares of the company’s stock valued at $328,000 after purchasing an additional 425 shares in the last quarter. Finally, Xponance Inc. grew its position in shares of LivaNova by 6.1% during the 4th quarter. Xponance Inc. now owns 7,762 shares of the company’s stock valued at $359,000 after purchasing an additional 445 shares in the last quarter. 97.64% of the stock is currently owned by hedge funds and other institutional investors.

LivaNova Company Profile

LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. The company operates through Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support segments. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products.